In the ever-evolving exosome field, the past year has witnessed remarkable progress. From Kimera's FDA IND approval to Brexogen's recent deal with HK inno.N and advancements in analytical technology, the landscape is rapidly advancing. Developing robust techniques is increasingly crucial, serving as the cornerstone for exosome therapeutics, alongside drug delivery applications and advancements.

The Exosome Characterization and Analytical Development Summit offers a comprehensive forum, equipping you with the skills needed to establish robust techniques, select the best instruments, ensure quality, and seamlessly navigate regulatory processes.

URLs:

Tickets: https://go.evvnt.com/2172701-2?pid=91 

Brochure: https://go.evvnt.com/2172701-3?pid=91 

Prices:

Drug Developer - Conference + 2 Workshops: USD 4197.00,

Drug Developer - Conference + 1 Workshop: USD 3598.00,

Drug Developer - Conference Only: USD 2999.00,

Academic and Research Institute - Conference + 2 workshops: USD 3597.00,

Academic and Research Institute - Conference + 1 workshop: USD 3098.00,

Academic and Research Institute - Conference Only: USD 2599.00,

Service and Solution Provider - Conference + 2 Workshops: USD 5097.00,

Service and Solution Provider - Conference + 1 Workshop: USD 4398.00,

Service and Solution Provider - Conference Only: USD 3699.00

Speakers: Brittany Mihelich, Principal Scientist, Astellas, Bruce Werber, Chief Executive Officer, BioXTek, Carla Mazzeo, Director of Research Development, AT Venture Center, Christopher Paradise, Vice President, Research and Development, RION Therapeutics, Desmond Pink, Chief Science Officer, Nanostics, Fahd Alhamdan, Research fellow, Harvard Medical School, Fatah Kashanchi, Professor, Microbiology, George Mason University, Gianluca Roma, Chief Executive Officer, EV Therapeutics, Hai-Yen Vu, Director of Analytics, Versatope Therapeutics, Heather Branscome, Researcher, PhD, George Mason University, Inkyu Lee, Research and Development Manager, Researcher, Shift Bio, Katie Gilligan, Head Of Research and Development, OmniSpirant, Kenneth Witwer, Associate Professor, Johns Hopkins University, Kristin Luther, Associate Director, Vesigen Therapeutics, Kuniko Kadoya, Director, AbbVie, Natasa Zarovni, Senior Director of Scientific Affairs, Exosomics Group, Romain de Rauville, Chief Business Officer, Exo Biologics, Shelley Hartman, Chief Executive Officer, Aegle Therapeutics